bersanlimab
Term · Oncology and biomedicine · MLC-T-ONC-011959
A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.
| Identifier | MLC-T-ONC-011959 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-intercellular adhesion molecule-1 monoclonal antibody BI-505 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011959",
"term": "bersanlimab",
"field": "Oncology and biomedicine",
"definition": "A fully human IgG1 monoclonal antibody directed against intercellular adhesion molecule-1 (ICAM-1 or CD54), with potential antineoplastic activity. Bersanlimab selectively binds to the adhesion protein ICAM-1, which may result in antibody-dependent cellular cytotoxicity (ADCC), hyper-cross-linking-induced apoptosis, and a decrease in cellular proliferation of ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers.",
"synonyms": [
"anti-intercellular adhesion molecule-1 monoclonal antibody BI-505"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/bersanlimab/"
}
Record 3,449 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.